Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 12
Submit an article Journal homepage
194
Views
0
CrossRef citations to date
0
Altmetric
Review

Application of Polysaccharides for Surface Modification of Nanomedicines

Kyung-Oh Doh1 Department of Physiology College of Medicine Yeungnam University317–1 Daemyung-dongDaeguRepublic of Korea
&
Yoon Yeo2 Department of Industrial & Physical Pharmacy College of Pharmacy Weldon School of Biomedical Engineering Purdue University575 Stadium Mall DriveWest [email protected];3 Biomedical Research Institute Korea Institute of Science & Technology Hwarangno 14-gil 5Seongbuk-guSeoul136-791Republic of Korea
Pages 1447-1456 | Published online: 04 Dec 2012

References

  • Matsumura Y , MaedaH. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46(12 Pt 1), 6387–6392 (1986).
  • Hobbs SK , MonskyWL, YuanFet al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607–4612 (1998).
  • Fukumura D , JainRK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res.74(2–3), 72–84 (2007).
  • Kao YJ , JulianoRL. Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim. Biophys. Acta.677(3–4), 453–461 (1981).
  • Patel HM , MoghimiSM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – the concept of tissue specificity. Adv. Drug Deliv. Rev.32(1–2), 45–60 (1998).
  • Moghimi SM , HunterAC, MurrayJC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.53(2), 283–318 (2001).
  • Abuchowski A , McCoyJR, PalczukNC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem.252(11), 3582–3586 (1977).
  • Abuchowski A , van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem.252(11), 3578–3581 (1977).
  • Klibanov AL , MaruyamaK, TorchilinVP, HuangL. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett.268(1), 235–237 (1990).
  • Gref R , MinamitakeY, PeracchiaMT, TrubetskoyV, TorchilinV, LangerR. Biodegradable long-circulating polymeric nanospheres. Science263(5153), 1600–1603 (1994).
  • Lee SW , YunMH, JeongSWet al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J. Control. Release 155(2), 262–271 (2011).
  • Kenausis GL , VorosJ, ElbertDLet al. Poly(L-lysine)-g-poly(ethylene glycol) layers on metal oxide surfaces: attachment mechanism and effects of polymer architecture on resistance to protein adsorption. J. Phys. Chem. B. 104(14), 3298–3309 (2000).
  • Du H , ChandaroyP, HuiSW. Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion. Biochim. Biophys. Acta.1326(2), 236–248 (1997).
  • Hong RL , HuangCJ, TsengYLet al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5(11), 3645–3652 (1999).
  • Hatakeyama H , AkitaH, HarashimaH. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev.63(3), 152–160 (2011).
  • Lehtinen J , MagarkarA, Stepniewski et al. Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine. Eur. J. Pharm. Sci.46(3), 121–130 (2012).
  • Remaut K , LucasB, BraeckmansK, DemeesterJ, De Smedt SC. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control. Release117(2), 256–266 (2007).
  • Mishra S , WebsterP, DavisME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol.83(3), 97–111 (2004).
  • Amoozgar Z , YeoY. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.4(2), 219–233 (2012).
  • Liu Z , JiaoY, WangY, ZhouC, ZhangZ. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev.60(15), 1650–1662 (2008).
  • Coviello T , MatricardiP, AlhaiqueF. Drug delivery strategies using polysaccharidic gels. Expert Opin. Drug Deliv.3(3), 395–404 (2006).
  • Passirani C , BarrattG, DevissaguetJP, LabarreD. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci.62(8), 775–785 (1998).
  • Passirani C , BarrattG, DevissaguetJP, LabarreD. Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res.15(7), 1046–1050 (1998).
  • Li J , HuoM, WangJet al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 33(7), 2310–2320 (2012).
  • Yuan ZX , ZhangZR, ZhuDet al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol. Pharm. 6(1), 305–314 (2009).
  • Rivkin I , CohenK, KofflerJ, MelikhovD, PeerD, MargalitR. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials31(27), 7106–7114 (2010).
  • Jiang G , ParkK, KimJet al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 89(7), 635–642 (2008).
  • Lemarchand C , GrefR, CouvreurP. Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm.58(2), 327–341 (2004).
  • Liu Z , JiaoY, WangY, ZhouC, ZhangZ. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev.60(15), 1650–1662 (2008).
  • Baldwin AD , KiickKL. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers94(1), 128–140 (2010).
  • Harrison JH . Dextran as a plasma substitute with plasma volume and excretion studies on control patients. Ann. Surg.139(2), 137–142 (1954).
  • Massia SP , StarkJ, LetbetterDS. Surface-immobilized dextran limits cell adhesion and spreading. Biomaterials21(22), 2253–2261 (2000).
  • Rodrigues JS , Santos-MagalhaesNS, CoelhoLC, CouvreurP, PonchelG, GrefR. Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. J. Control. Release92(1–2), 103–112 (2003).
  • Lemarchand C , CouvreurP, BesnardM, CostantiniD, GrefR. Novel polyester-polysaccharide nanoparticles. Pharm. Res.20(8), 1284–1292 (2003).
  • Bonnemain B . Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J. Drug Target.6(3), 167–174 (1998).
  • Moore A , MarecosE, BogdanovA Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology214(2), 568–574 (2000).
  • Lemarchand C , GrefR, PassiraniCet al. Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials 27(1), 108–118 (2006).
  • Labarre D , VauthierC, ChauvierreC, PetriB, MüllerR, ChehimiMM. Interactions of blood proteins with poly(isobutylcyano-acrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials26(24), 5075–5084 (2005).
  • Vauthier C , PerssonB, LindnerP, CabaneB. Protein adsorption and complement activation for di-block copolymer nanoparticles. Biomaterials32(6), 1646–1656 (2011).
  • Alhareth K , VauthierC, BourassetF, GueutinC, PonchelG, MoussaF. Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur. J. Pharm. Biopharm.81(2), 453–457 (2012).
  • Kemp MM , LinhardtRJ. Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2(1), 77–87 (2010).
  • Linhardt RJ . 2003. Claude S Hudson Award address in carbohydrate chemistry. heparin: structure and activity. J. Med. Chem.46(13), 2551–2564 (2003).
  • Oschatz C , MaasC, LecherBet al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34(2), 258–268 (2011).
  • Crum R , SzaboS, FolkmanJ. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science230(4732), 1375–1378 (1985).
  • Folkman J , LangerR, LinhardtRJ, HaudenschildC, TaylorS. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science221(4612), 719–725 (1983).
  • Lundin L , LarssonH, KreugerJet al. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 275(32), 24653–24660 (2000).
  • Yoshitomi Y , NakanishiH, KusanoYet al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 207(2), 165–174 (2004).
  • Yu MK , LeeDY, KimYSet al. Antiang-iogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm. Res. 24(4), 705–714 (2007).
  • Park K , KimYS, LeeGYet al. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm. Res. 25(12), 2786–2798 (2008).
  • Chauvierre C , MardenMC, VauthierC, LabarreD, CouvreurP, LeclercL. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials25(15), 3081–3086 (2004).
  • Chauvierre C , ManchandaR, LabarreD, VauthierC, MardenMC, LeclercL. Artificial oxygen carrier based on polysaccharides-poly(alkylcyanoacrylates) nanoparticle templates. Biomaterials31(23), 6069–6074 (2010).
  • Park K , KimK, KwonICet al. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 20(26), 11726–11731 (2004).
  • Park K , LeeGY, KimYSet al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J. Control. Release 114(3), 300–306 (2006).
  • Lee E , KimYS, BaeSMet al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int. J. Cancer 124(12), 2755–2765 (2009).
  • Kumar MN , MuzzarelliRA, MuzzarelliC, SashiwaH, DombAJ. Chitosan chemistry and pharmaceutical perspectives. Chem. Rev.104(12), 6017–6084 (2004).
  • Bernkop-Schnurch A , DunnhauptS. Chitosan-based drug delivery systems. Eur. J. Pharm. Biopharm.81(3), 463–469 (2012).
  • Park JH , SaravanakumarG, KimK, KwonIC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev.62(1), 28–41 (2010).
  • Son YJ , JangJS, ChoYWet al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release 91(1–2), 135–145 (2003).
  • Lee E , LeeJ, LeeIHet al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem. 51(20), 6442–6449 (2008).
  • Bowman K , LeongKW. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine1(2), 117–128 (2006).
  • van der Merwe SM , VerhoefJC, VerheijdenJHM, KotzéAF, JungingerHE. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharm.58(2), 225–235 (2004).
  • Ono K , SaitoY, YuraHet al. Photocrosslinkable chitosan as a biological adhesive. J. Biomed. Mater. Res. 49, 289–295 (2000).
  • Amsden BG , SukartoA, KnightDK, ShapkaSN. Methacrylated glycol chitosan as a photopolymerizable biomaterial. Biomacromolecules8(12), 3758–3766 (2007).
  • Park JH , KwonS, Nam J-O et al. Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery. J. Control. Release95(3), 579–588 (2004).
  • Park K , Kim J-H, Nam YS et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J. Control. Release122(3), 305–314 (2007).
  • Min KH , ParkK, Kim Y-S et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release127(3), 208–218 (2008).
  • Yoo HS , LeeJE, ChungH, KwonIC, JeongSY. Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J. Control. Release103(1), 235–243 (2005).
  • Amoozgar Z , ParkJ, LinQ, YeoY. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol. Pharm.9(5), 1262–1270 (2012).
  • Xu P , BajajG, ShuggT, Van Alstine WG, Yeo Y. Zwitterionic chitosan derivatives for pH-sensitive stealth coating. Biomacromolecules11(9), 2352–2358 (2010).
  • Na JH , KooH, LeeSet al. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials 32(22), 5252–5261 (2011).
  • Lee SJ , ParkK, OhYKet al. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials 30(15), 2929–2939 (2009).
  • Kim JH , KimYS, KimSet al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 111(1–2), 228–234 (2006).
  • Kim JH , KimYS, ParkKet al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 127(1), 41–49 (2008).
  • Lee SJ , HuhMS, LeeSYet al. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed. Engl. 51(29), 7203–7207 (2012).
  • Nam HY , KwonSM, ChungHet al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 135(3), 259–267 (2009).
  • Zhou J , RomeroG, RojasE, MaL, MoyaS, GaoC. Layer by layer chitosan/alginate coatings on poly(lactide-co-glycolide) nanoparticles for antifouling protection and folic acid binding to achieve selective cell targeting. J. Colloid Interface Sci.345(2), 241–247 (2010).
  • Pastor E , MatveevaE, Valle-GallegoA, GoycooleaFM, Garcia-FuentesM. Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles. Colloids Surf. B Biointerfaces88(2), 601–609 (2011).
  • Chung YI , KimJC, KimYHet al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated pluronic on tumor targeting. J. Control. Release 143(3), 374–382 (2010).
  • Chong BF , BlankLM, McLaughlinR, NielsenLK. Microbial hyaluronic acid production. Appl. Microbiol. Biotechnol.66(4), 341–351 (2005).
  • Oh EJ , ParkK, KimKSet al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J. Control. Release 141(1), 2–12 (2010).
  • Stern R , AsariAA, SugaharaKN. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol.85(8), 699–715 (2006).
  • Feinberg RN , BeebeDC. Hyaluronate in vasculogenesis. Science220(4602), 1177–1179 (1983).
  • West DC , HampsonIN, ArnoldF, KumarS. Angiogenesis induced by degradation products of hyaluronic acid. Science228(4705), 1324–1326 (1985).
  • Takahashi Y , LiL, KamiryoMet al. Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J. Biol. Chem. 280(25), 24195–24204 (2005).
  • Aruffo A , StamenkovicI, MelnickM, UnderhillCB, SeedB. CD44 is the principal cell surface receptor for hyaluronate. Cell61(7), 1303–1313 (1990).
  • Weigel JA , WeigelPH. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem.278(44), 42802–42811 (2003).
  • Hardwick C , HoareK, OwensRet al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J. Cell Biol. 117(6), 1343–1350 (1992).
  • Banerji S , NiJ, WangSXet al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144(4), 789–801 (1999).
  • Bajaj G , KimMR, MohammedSI, YeoY. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J. Control. Release158(3), 386–392 (2012).
  • Luo Y , PrestwichGD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem.10(5), 755–763 (1999).
  • Eliaz RE , SzokaFC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res.61(6), 2592–2601 (2001).
  • Luo Y , BernshawNJ, LuZR, KopecekJ, PrestwichGD. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res.19(4), 396–402 (2002).
  • Wu JL , LiuCG, WangXL, HuangZH. Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers. J. Mater. Sci. Mater. Med.23(8), 1921–1929 (2012).
  • Choi KY , YoonHY, KimJHet al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 5(11), 8591–8599 (2011).
  • Fischer D , LiY, AhlemeyerB, KrieglsteinJ, KisselT. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials24(7), 1121–1131 (2003).
  • Han SE , KangH, ShimGYet al. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J. Drug Target 17(2), 123–132 (2009).
  • Park K , HongSW, HurWet al. Target specific systemic delivery of TGF-beta siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials 32(21), 4951–4958 (2011).
  • Jiang G , ParkK, KimJ, KimKS, HahnSK. Target specific intracellular delivery of siRNA/PEI–HA complex by receptor mediated endocytosis. Mol. Pharm.6(3), 727–737 (2009).
  • Takei Y , MaruyamaA, FerdousAet al. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. FASEB J. 18(6), 699–701 (2004).
  • Xu P , QuickGK, YeoY. Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials30(29), 5834–5843 (2009).
  • Ito T , Iida-TanakaN, NiidomeTet al. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J. Control. Release 112(3), 382–388 (2006).
  • Tomiyama T , ToitaR, KangJHet al. Effect of introduction of chondroitin sulfate into polymer-peptide conjugate responding to intracellular signals. Nanoscale Res. Lett. 6(1), 532 (2011).
  • Lee CT , HuangCP, LeeYD. Synthesis and characterizations of amphiphilic poly(L-lactide)-grafted chondroitin sulfate copolymer and its application as drug carrier. Biomol. Eng.24(1), 131–139 (2007).
  • Lee CT , HuangCP, LeeYD. Preparation of amphiphilic poly(L-lactide)-graft-chondroitin sulfate copolymer self-aggregates and its aggregation behavior. Biomacromolecules7(4), 1179–1186 (2006).
  • Park W , ParkSJ, NaK. Potential of self-organizing nanogel with acetylated chondroitin sulfate as an anti-cancer drug carrier. Colloids Surf. B Biointerfaces79(2), 501–508 (2010).
  • Lim J , HammoudiT, Bratt-LealAet al. Development of nano- and microscale chondroitin sulfate particles for controlled growth factor delivery. Acta Biomater. 7(3), 986–995 (2011).
  • Hamada K , YoshiharaC, ItoTet al. Antitumor effect of chondroitin sulfate-coated ternary granulocyte macrophage-colony-stimulating factor plasmid complex for ovarian cancer. J. Gene Med. 14(2), 120–127 (2012).
  • Pathak A , KumarP, ChuttaniKet al. Gene expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate-PEI nanoconstructs mediated tumor gene therapy. ACS Nano 3(6), 1493–1505 (2009).
  • Henke CA , RoongtaU, MickelsonDJ, KnutsonJR, McCarthyJB. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J. Clin. Invest.97(11), 2541–2552 (1996).
  • Kurosaki T , KitaharaT, KawakamiSet al. The development of a gene vector electrostatically assembled with a polysaccharide capsule. Biomaterials 30(26), 4427–4434 (2009).
  • Uchida S , ItakaK, ChenQet al. Combination of chondroitin sulfate and polyplex micelles from poly(ethylene glycol)-poly{N´-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} block copolymer for prolonged in vivo gene transfection with reduced toxicity. J. Control. Release 155(2), 296–302 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.